Compare Hormel Foods Corp (HRL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Zimmer Biomet Holdings Inc — how do they compare? Hormel Foods Corp trades at $19.19 (market cap $10.69B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HRL | ZBH | |
|---|---|---|
Market Cap | $10.69B | $16.95B |
Volume | 10,041,387 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $103.98 |
52-Week Low | $19.19 | $79.58 |
Typical Hold Time | 99 Days | 89 Days |
Enterprise Value | $12.67B | $24.02B |
Dividend Yield | 6.02% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.42, down 0.66% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, though recent quarters beat EPS estimates. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, while maintaining a 60-year dividend streak. Cash flow trends show improvement from 2025's negative $71M to projected 2026 positive $245M.
HRL presents a value opportunity with 25% upside to consensus target of $24.25, supported by dividend stability. However, declining profit margins and elevated valuation multiples pose headwinds. The Brakebush integration execution and consumer spending trends will be critical for reversing earnings pressure amid competitive food markets.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
